3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Filgrastim
15
Carboplatin
10
Ifosfamide
9
Doxorubicin
9
Cyclophosphamide
9
Peripheral Blood Stem Cell Transplantation
7
pembrolizumab
6
Radiotherapy
6
Gemcitabine
6
Temozolomide
5
Etoposide
5
Cisplatin
5
Paclitaxel
4
Docetaxel
4
Amifostine
4
aldesleukin
3
aflibercept
3
Trastuzumab
3
Specimen Handling
3
Radiosurgery
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Biopsy
3
tislelizumab
2
sodium thiosulfate
2
selinexor
2
pazopanib
2
palbociclib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
tinostamustine
×
Gynecologic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts